S2007
|
SWOG
|
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2010
|
SWOG
|
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen)
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
S2011
|
SWOG
|
Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP Trial
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2012
|
SWOG
|
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2013
|
SWOG
|
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
S2015
|
SWOG
|
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2101
|
SWOG
|
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2104
|
SWOG
|
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2107
|
SWOG
|
Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2108CD
|
SWOG
|
A Cluster Randomized Trial Comparing An Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|